Nurtec Odt

rimegepant sulfate · RIMEGEPANT SULFATE 75 mg/1 · Tablet, Orally Disintegrating · Oral · Pfizer Laboratories Div Pfizer Inc

NDC 72618-3001-02 · 4 DOSE PACK in 1 CARTON / 1 BLISTER PACK in 1 DOSE PACK / 2 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK · NDA · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 72618-3000-02) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built

Data sources

CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)

Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ

$129.07per unit

middle half $126.00–$135.49 · 4,443 plans · Apr 1, 2026

Est. net of rebatesⓘ

$77.44–$96.80

brand drug — est. 25-40% rebate off the price at left

Coverage & restrictions

81%of plans cover it

tier 3 · prior auth 97% · step therapy 0% · qty limit 95%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for rimegepant sulfate (oral solid) in the next 90 days

sole-source market · price up 4% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill · avg $1,465.45 per prescription
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: NDA212728
TE code: —
Approval date: Feb 27, 2020
Patents / exclusivity: 3 patents, 0 exclusivities

Type	Number / code	Expires
patent	11083724	Mar 25, 2039
patent	8314117	Feb 27, 2034
patent	8759372	Feb 25, 2033

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

Class II · TerminatedMar 15, 2021
Cardinal Health Inc. — CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Manufacturers of rimegepant sulfate (Tablet, Orally Disintegrating)

Labeler	Strength	First seen	Last seen
Pfizer Laboratories Div Pfizer Inc	RIMEGEPANT SULFATE 75 mg/1	Jul 15, 2026	Sep 3, 2026
Catalent U.K. Swindon Zydis Limited	RIMEGEPANT SULFATE 75 mg/1	Jul 15, 2026	Sep 2, 2026
Sportpharm LLC	RIMEGEPANT SULFATE 75 mg/1	Jul 15, 2026	Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Nurtec Odt — NDC 72618-3001-02," retrieved September 3, 2026, https://drugdashboards.com/drug/72618300102.

Free to cite with attribution — see how the data is put together.